- Barrons.com•15 hours ago
After hosting a dinner with Gilead Sciences (GILD), Piper Jaffray's Joshua Schimmer and team contend that investor attention is finally beginning to turn away from hepatitis C. They explain: We hosted ...
- Reuters•16 hours ago
The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments. The Pharmacovigilance Risk Assessment Committee (PRAC), part of the EMA, said it suspected the reactivation of the hepatitis B virus was due to the rapid reduction of the hepatitis C virus, which is known to suppress the hepatitis B virus.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||72.35 x 100|
|Ask||72.45 x 400|
|Day's Range||72.16 - 73.59|
|52 Week Range||71.39 - 104.79|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.70|
|Dividend & Yield||1.88 (2.55%)|
|1y Target Est||N/A|